A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

Clinical trial NCT06902545 · RECRUITING

Trial details

NCT number: NCT06902545
Sponsor: Astellas Pharma Korea, Inc.
Status: RECRUITING
Study type: OBSERVATIONAL

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer Metastatic Gastric Adenocarcinoma or Cancer Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

Start date: 2025-04-03
Primary completion: 2030-07-31
Enrollment: 377

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.